145 related articles for article (PubMed ID: 9895216)
1. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity.
Winn LM; Wells PG
Free Radic Biol Med; 1999 Feb; 26(3-4):266-74. PubMed ID: 9895216
[TBL] [Abstract][Full Text] [Related]
2. Oxidative damage in chemical teratogenesis.
Wells PG; Kim PM; Laposa RR; Nicol CJ; Parman T; Winn LM
Mutat Res; 1997 Dec; 396(1-2):65-78. PubMed ID: 9434860
[TBL] [Abstract][Full Text] [Related]
3. Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice.
Ozolins TR; Siksay DL; Wells PG
J Pharmacol Exp Ther; 1996 May; 277(2):945-53. PubMed ID: 8627577
[TBL] [Abstract][Full Text] [Related]
4. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity.
Winn LM; Wells PG
Mol Pharmacol; 1995 Jul; 48(1):112-20. PubMed ID: 7623765
[TBL] [Abstract][Full Text] [Related]
5. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis.
Winn LM; Wells PG
Free Radic Biol Med; 1997; 22(4):607-21. PubMed ID: 9013124
[TBL] [Abstract][Full Text] [Related]
6. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase.
Wells PG; Zubovits JT; Wong ST; Molinari LM; Ali S
Toxicol Appl Pharmacol; 1989 Feb; 97(2):192-202. PubMed ID: 2493687
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor L-buthionine-(S,R)-sulfoximine and by the glutathione depletor diethyl maleate.
Wong M; Helston LM; Wells PG
Teratology; 1989 Aug; 40(2):127-41. PubMed ID: 2772848
[TBL] [Abstract][Full Text] [Related]
8. Embryonic catalase protects against ethanol embryopathies in acatalasemic mice and transgenic human catalase-expressing mice in embryo culture.
Miller-Pinsler L; Wells PG
Toxicol Appl Pharmacol; 2015 Sep; 287(3):232-9. PubMed ID: 26074427
[TBL] [Abstract][Full Text] [Related]
9. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice.
Yu WK; Wells PG
Toxicol Appl Pharmacol; 1995 Mar; 131(1):1-12. PubMed ID: 7878664
[TBL] [Abstract][Full Text] [Related]
10. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues.
Liu L; Wells PG
Free Radic Biol Med; 1995 Nov; 19(5):639-48. PubMed ID: 8529923
[TBL] [Abstract][Full Text] [Related]
11. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs?
Azarbayjani F; Danielsson BR
Epilepsia; 2002 May; 43(5):457-68. PubMed ID: 12027905
[TBL] [Abstract][Full Text] [Related]
12. Embryonic catalase protects against endogenous and phenytoin-enhanced DNA oxidation and embryopathies in acatalasemic and human catalase-expressing mice.
Abramov JP; Wells PG
FASEB J; 2011 Jul; 25(7):2188-200. PubMed ID: 21478259
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phenytoin bioactivation and teratogenicity by dietary n-3 fatty acids in mice.
Kubow S
Lipids; 1992 Sep; 27(9):721-8. PubMed ID: 1487972
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds.
Wells PG; Nagai MK; Greco GS
Toxicol Appl Pharmacol; 1989 Mar; 97(3):406-14. PubMed ID: 2609340
[TBL] [Abstract][Full Text] [Related]
15. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets of chemical teratogenesis.
Liu L; Wells PG
Toxicol Appl Pharmacol; 1994 Apr; 125(2):247-55. PubMed ID: 8171432
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen.
Lum JT; Wells PG
Teratology; 1986 Feb; 33(1):53-72. PubMed ID: 3738810
[TBL] [Abstract][Full Text] [Related]
17. Phenytoin covalent binding and embryopathy in mouse embryos co-cultured with maternal hepatocytes from mouse, rat, and rabbit.
Ozolins TR; Wiley MJ; Wells PG
Biochem Pharmacol; 1995 Nov; 50(11):1831-40. PubMed ID: 8615862
[TBL] [Abstract][Full Text] [Related]
18. Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage.
Azarbayjani F; Danielsson BR
Teratology; 2001 Mar; 63(3):152-60. PubMed ID: 11283972
[TBL] [Abstract][Full Text] [Related]
19. Effects of N-acetylcysteine on fetal development and on phenytoin teratogenicity in mice.
Wong M; Wells PG
Teratog Carcinog Mutagen; 1988; 8(2):65-79. PubMed ID: 2899918
[TBL] [Abstract][Full Text] [Related]
20. Evidence for Ras-dependent signal transduction in phenytoin teratogenicity.
Winn LM; Wells PG
Toxicol Appl Pharmacol; 2002 Nov; 184(3):144-52. PubMed ID: 12460742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
